Biotech
Commented by Nico Popp on July 23rd, 2026 | 07:50 CEST
Panic in the Multi-Billion-Dollar Market: Novo Nordisk and Halozyme Therapeutics Face Headwinds—BioNxt Solutions Nears a Turning Point
The global pharmaceutical market is worth hundreds of billions of dollars. Yet one of the industry's most surprising realities is that success increasingly depends not only on the active ingredient itself but also on how it is delivered. This does not refer to the cardboard box, but to the dosage form. Whenever patents expire, and blockbuster drugs face competition, innovative biotech companies seize the opportunity. New drug delivery technologies can transform well-known substances into more effective medicines, reduce side effects, and open up entirely new treatment options for patients. While established pharmaceutical giants spend vast sums defending market exclusivity, agile second-tier biotech companies are driving innovation through next-generation drug delivery platforms.
Read
Commented by Nico Popp on July 23rd, 2026 | 07:40 CEST
The Patent Cliff Could Cost Billions: How Bayer and Merck & Co. Respond—and How Vidac Pharma Is Gaining Momentum
Leading oncology centers have long recognized that the fight against cancer cannot be won with just one active ingredient. It is increasingly clear that lasting treatment success depends on combining multiple therapeutic approaches. For years, oncologists relied heavily on conventional chemotherapy. Yet tumours consistently prove resilient and demand more complex therapies. Since patents on many active ingredients are expiring anyway, new, complementary forms of therapy are gaining prominence. One of these therapies targets the disrupted energy metabolism of cancer cells and shows promise. We examine the market and introduce an exciting biotech company that few experts are familiar with.
Read
Commented by Matthias Schomber on July 22nd, 2026 | 07:55 CEST
Millions in Losses at Eutelsat! Warning Sparks Panic at Evotec! Can Zefiro Methane Save Your Portfolio?
The geopolitical situation is currently escalating dramatically. The latest news from the Middle East is coming in fast and furious. A massive military exchange between the US and Iran threatens to profoundly shake the global economy. Burning oil refineries in Kuwait, dead soldiers, and wailing sirens in the Gulf state of Bahrain paint a grim picture of the current security situation. Such rapidly escalating crises are driving oil prices sky-high and have the potential to send shockwaves through international financial markets. In these particularly turbulent times, many investors are desperately seeking safe havens. While once-coveted AI and tech stocks, as well as biotech hopefuls, are collapsing under the weight of global uncertainty and, in some cases, their own internal issues, lucrative niche markets are increasingly coming into focus. Today, we take a look at three different stocks. First, we examine the severe setback at Evotec, the costly strategic hurdles at Eutelsat, and the astonishing resilience of Zefiro Methane.
Read
Commented by Fabian Lorenz on July 16th, 2026 | 07:10 CEST
Evotec Shocks the Market! Will First Majestic Silver and Lahontan Gold Take Off?
Biotech stocks have not exactly been investor favourites this year. And now Evotec has delivered yet another shock. It was already known that the company was undergoing a comprehensive restructuring. Nevertheless, it had recently seemed as though the share price was finding a bottom in the EUR 4-5 range. But then came the shock. The significant downward revision of its forecast and the expected high EBITDA loss caused the share price to plummet. In contrast, Lahontan Gold is shining with relative strength. While it cannot escape the negative sentiment in the gold sector, the odds are good that the share price will take off again soon. After all, the company is on the verge of transitioning from an explorer to a producer. And what about First Majestic Silver? This core investment in the silver sector recently reported its second-quarter production figures.
Read
Commented by André Will-Laudien on July 15th, 2026 | 11:00 CEST
Sharp Swings in the Life Sciences Sector: Bayer, Vidac Pharma, BioNTech, Moderna, and Evotec in the Spotlight
Things are really heating up here! Cancer research is currently undergoing a historic turning point thanks to the convergence of cell analysis and digital precision. With a new management team, BioNTech is attempting to transition its revolutionary mRNA platform from COVID-19 to personalized cancer vaccines, while Bayer is strategically focusing on next-generation targeted radionuclide therapies. In the agricultural sector, the first signs of relief are finally emerging, as glyphosate is now being negotiated at the supranational level and has been classified as non-harmful by US authorities. At the same time, drug discovery company Evotec is grappling with a new revenue warning—and this one is particularly severe. Vidac Pharma is also coming into focus as a highly specialized innovator by blocking cancer metabolism to decisively manipulate the tumour microenvironment. These four distinct approaches impressively demonstrate that the victory over cancer no longer lies solely in traditional chemotherapies, but rather in highly specialized biotech companies and data-driven alliances. With so much news on the table, volatility is sure to follow.
Read
Commented by Matthias Schomber on July 15th, 2026 | 08:45 CEST
AI, Oncology, and Defense: TeamViewer, BioNTech, and Antimony Resources—A Great Mix for Your Portfolio!
Created and published on behalf of Antimony Resources Corp.
The stock market is a place of extremes, and today we are looking at a trio—TeamViewer, BioNTech, and Antimony Resources—that comes from three different sectors. There is a German software pioneer that, after painful setbacks, is suddenly showing clear signs of life again. There is a once-celebrated vaccine hero pumping billions into a risky but revolutionary future in cancer therapy—while still holding a substantial cash reserve. And then there is a Canadian mineral explorer digging deep into the earth for a material without which our modern world would simply grind to a halt—one that is also crucial for the defense industry. It is precisely this mix of a software-AI turnaround, a biotech-oncology transformation, and mineral potential that makes the market so incredibly exciting. Join us on a journey through three fascinating corporate stories.
Read
Commented by Fabian Lorenz on July 14th, 2026 | 07:00 CEST
Bayer and Novo Nordisk Celebrate a Comeback! Is BioNxt Solutions Next?
With its GLP-1 therapy in tablet form, Novo Nordisk has returned to success on the stock market. Since April, the Danish pharmaceutical company's stock has risen by nearly 50% to around EUR 43. New research results are now being presented. Bayer has also recently celebrated a comeback on the stock market. Following the landmark glyphosate ruling by the US Supreme Court, hopes are growing that the company will be able to focus more strongly on its core business again in the future. To that end, the Leverkusen-based company has secured EUR 3 billion. BioNxt Solutions could be poised for a comeback. The biotech company's stock has nearly halved in value this year. Yet the news flow is positive and points to rising prices.
Read
Commented by Armin Schulz on July 9th, 2026 | 07:35 CEST
From Injection Blockbusters to an Oral Future: An Analysis of Novo Nordisk, BioNxt Solutions, and Pfizer in This Race
The weight-loss injection has fundamentally transformed the pharmaceutical industry and set in motion a business with billion-dollar potential, but this initial gold rush is over. The industry is undergoing a disruptive transformation in which more convenient oral alternatives are increasingly replacing the unpleasant injection. This development is shifting the balance of power, giving latecomers a historic opportunity while the market leaders must defend their dominance. The battle for power in obesity treatment has begun anew. Which company will take the lead in the next phase? Today, we take a closer look at Novo Nordisk, BioNxt Solutions, and Pfizer.
Read
Commented by Nico Popp on July 7th, 2026 | 07:35 CEST
Pulling the Plug on Cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma
Without health, everything else is nothing. In recent years, companies in the pharmaceutical and biotech sectors have already achieved major successes when it comes to easing the suffering of the chronically ill and of cancer patients. Progress is increasingly being made thanks to innovative platform approaches that make it possible to combine different technologies. One example is thermodynamic and metabolic platforms. We examine the latest trends and explain how investors can also benefit from innovations in biotechnology.
Read
Commented by Matthias Schomber on July 6th, 2026 | 07:00 CEST
Burry's Short Attack on Micron Technology, BioNTech's Radical Overhaul and Strategic Resources: a Still-Quiet Commodities Player!
While the AI boom continues to promise enormous profits, the first cracks are beginning to appear. High-profile investors are suddenly betting against some of Wall Street's former—and in some cases already fallen—favourites. Will Micron Technology stage a successful turnaround, or is a deeper correction still ahead? At the same time, Germany's biotech sector is undergoing a period of profound change. Cost-cutting programs worth billions of euros and sweeping strategic realignments are putting investors' conviction to the test. Away from the spotlight, a potentially transformative story is also unfolding in the commodities sector. Investors seeking early exposure to the long-term trend in industrial decarbonization may want to take a closer look at Strategic Resources. We examine three companies from three very different industries—each offering a distinct investment opportunity.
Read